| Disease | M3 ANLL (de novo); a very few cases of t(15;17) in therapy-related leukaemia (t-ANLL) have been reported. |
| Phenotype / cell stem origin | t(15;17) is quasi pathognomonic of M3 ANLL (acute promyelocytic leukemia, or APL). |
| Epidemiology | found in 10% of adult ANLL; annual incidence: 1/106, similar to the incidence of the t(8;21) ; any age, but frequent in the young adult; sex ratio 1M/1F. |
| Clinics | WBC and platelets may be lower than in other ANLL; coagulopathy |
| Cytology | large cells with myeloperoxidase positive cytoplasmic granulations (microgranular forms are called variant M3 ANLL, and are often hyperleucocytic); bundles of Auer rods. |
| |  |
|
| t(15;17)(q24;21) is associated conbsistently with AML M3. This chromosomal abnormality first appeared to be confined to the characteristic or morphologically typical M3 AML or "hypergranular promyelocytic leukemia", defined by bone marrow replacement with highly granulated blast cells. The nuclear size and shape is irregular and highly variable; they are often kidney-shaped or bilobed. The cytoplasm is completely occupied by densely packed or even coalescent large granules, staining bright pink, red or purple by MGG. In some cells the cytoplasm is filled with fine dust-like granules. Characteristic cells containing bundles of Auer rods ("faggot cells") randomly distributed in the cytoplasm, although frequent, are not present in all cases. Auer rods in M3 are usually larger than in other AML and they may have a characteristic morphology at the ultrastructural level. In some cases, the cytoplasmic granules are so large and/or numerous that they totally obscure the cell, rendering the nuclear cytoplasmic limit indistinct. In M3 AML, MPO is always strongly positive in all blast cells, with the reaction product covering the whole cytoplasm and often the nucleus too - Text and iconography Courtesy Georges Flandrin 2001. |
|
| Treatment | one of the rare leukaemia where treatment is an emergency, as intra vascular coagulation is prominent, causing a high rate (10 to 40%) of early mortality, mainly due to cerebral haemorrhage; with the recent differentiation therapy using all trans-retinoic acid (with combined chemotherapy), CR is obtained in 80-90% of cases; this is the only cancer which, to date, can be treated by differentiation therapy. |
| Prognosis | early death rate still at 15-20%; combination of retinoic acid and chemotherapy prolonged survival significantly: survival at 1 yr and at 3 yrs are stable at 70%, instead of a 30 to 40 % 3 yr survival previously. |
| |  |
| |
| |
PMLRARA in t(15;17)(q24;q21) - Courtesy Maria no Rocchi, Resources for Molecular Cytogenetics. |
| |
| Cytogenetics Morphological | although primary anomaly in most cases, t(15;17) can also occur in rare occurrences at acutisation (of promyelocytic type, of course) of a CML with the usual t(9;22). |
| Additional anomalies | +8 in 1/3 of cases; del (7q); del(9q) rare. |
| Variants | 1- true variants, i.e. three way complex t(15;Var;17) exist; they demonstrated that the crucial event lies on der(15), which receives the end part of chromosome 17. 2- related translocations, rarely observed, involve a commun breakpoint in 17q21, within RARa, fused with different partners, in: t(11;17)(q23;q21), fusion with PLZF, t(5;17)(q32;q12), fusion with NPM1, and t(11;17)(q13;q21), fusion with NUMA. |
| Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17. |
| Borrow J, Goddard AD, Sheer D, Solomon E |
| Science (New York, N.Y.). 1990 ; 249 (4976) : 1577-1580. |
| PMID 2218500 |
| |
| The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. |
| de Thˆ© H, Chomienne C, Lanotte M, Degos L, Dejean A |
| Nature. 1990 ; 347 (6293) : 558-561. |
| PMID 2170850 |
| |
| Translocation breakpoint of acute promyelocytic leukemia lies within the retinoic acid receptor alpha locus. |
| Alcalay M, Zangrilli D, Pandolfi PP, Longo L, Mencarelli A, Giacomucci A, Rocchi M, Biondi A, Rambaldi A, Lo Coco F |
| Proceedings of the National Academy of Sciences of the United States of America. 1991 ; 88 (5) : 1977-1981. |
| PMID 1848017 |
| |
| Cytogenetic studies in acute promyelocytic leukemia: a survey of secondary chromosomal abnormalities. |
| Berger R, Le Coniat M, Derrˆ© J, Vecchione D, Jonveaux P |
| Genes, chromosomes & cancer. 1991 ; 3 (5) : 332-337. |
| PMID 1797083 |
| |
| Genomic variability and alternative splicing generate multiple PML/RAR alpha transcripts that encode aberrant PML proteins and PML/RAR alpha isoforms in acute promyelocytic leukaemia. |
| Pandolfi PP, Alcalay M, Fagioli M, Zangrilli D, Mencarelli A, Diverio D, Biondi A, Lo Coco F, Rambaldi A, Grignani F |
| The EMBO journal. 1992 ; 11 (4) : 1397-1407. |
| PMID 1314166 |
| |
| Acute promyelocytic leukemia. |
| Warrell RP Jr, de Thˆ© H, Wang ZY, Degos L |
| The New England journal of medicine. 1993 ; 329 (3) : 177-189. |
| PMID 8515790 |
| |
| Treatment of newly diagnosed acute promyelocytic leukemia (APL) by all transretinoic acid (ATRA) combined with chemotherapy: The European experience. European APL Group. |
| Fenaux P, Chastang C, Chomienne C, Castaigne S, Sanz M, Link H, Lˆwenberg B, Fey M, Archim-Baud E, Degos L |
| Leukemia & lymphoma. 1995 ; 16 (5-6) : 431-437. |
| PMID 7787753 |
| |
